PEG-MGF vs Octreotide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PEG-MGF
PEG-MGF (PEGylated Mechano Growth Factor) is a variant of IGF-1 that is produced in response to muscle damage. PEGylation extends its half-life from minutes to several hours, making it practical for use.
Full details →Octreotide
Octreotide (Sandostatin) is a synthetic somatostatin analog FDA-approved for acromegaly, carcinoid tumors, and VIPomas. It inhibits growth hormone and various GI hormones.
Full details →Side-by-Side Comparison
| Aspect | PEG-MGF | Octreotide |
|---|---|---|
| Mechanism | Activates muscle satellite cells (stem cells) and promotes their fusion to existing muscle fibers for repair and growth. MGF is produced naturally in response to mechanical stress on muscles. | Binds to somatostatin receptors (primarily SSTR2 and SSTR5) to inhibit GH, glucagon, insulin, and gastric secretions. Reduces blood flow to GI tract and inhibits tumor hormone secretion. |
| Typical Dosage | Research protocols typically use 200-400mcg injected into targeted muscle groups 2-3 times weekly, usually post-workout. | Varies by indication. Acromegaly: 50-100mcg three times daily initially, up to 500mcg TID. LAR (long-acting): 20-30mg IM every 4 weeks. |
| Administration | Intramuscular injection, ideally into muscles trained that day. Best administered post-workout when satellite cell activation is relevant. | Subcutaneous injection for immediate-release (between meals). Intramuscular for LAR depot form. Requires monitoring of gallbladder, glucose, and thyroid. |
| Side Effects | Injection site soreness, potential hypoglycemia, and localized swelling. Generally well-tolerated. | GI effects (diarrhea, nausea, abdominal pain), gallstones (up to 25% of long-term users), injection site reactions, and blood glucose changes. |
| Best For |